Autres langues Marvel Biosciences Corp.

Actions

MRVL

CA57384M1077

Marché Fermé - Toronto S.E. Autres places de cotation 21:22:39 29/04/2024			Varia. 5j.	Varia. 1 janv.
0,15 ^CAD	+3,45 %		+11,11 %	+87,50 %

26/03	Marvel Biosciences Corp. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 janvier 2024	CI
25/03	Marvel Biosciences annonce des résultats intermédiaires positifs pour le MB-204	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	26/03
Marvel Biosciences Announces Positive Interim Results For MB-204	25/03
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Positive Interim Results on Tau Phosphorylation with MB-204	25/03
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204	25/03
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB204	12/03
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204	12/03
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20/02
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University	20/02
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20/02
Marvel Biosciences Announces Closing of Non-Brokered Private Placement	19/01
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding	19/01
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel	08/01
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	18/12
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	28/11
Marvel Biosciences Invited to Test MB-204 on Autism by French University	16/11
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials	22/08/23
Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23/06/23
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to enter Human Trials	21/04/23
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	30/03/23
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204	09/03/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Marvel Biosciences Corp.

Actions

MRVL

CA57384M1077

Autres langues

Filtres